LJPC 1010

Drug Profile

LJPC 1010

Alternative Names: LJPC-1010

Latest Information Update: 11 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Polysaccharides
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 08 May 2015 LJPC 1010 is available for licensing as of 08 May 2015. www.ljpc.com
  • 08 May 2015 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (PO)
  • 08 May 2015 La Jolla Pharmaceutical Company terminates a phase I trial in Non-alcoholic steatohepatitis prior to enrolment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top